Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

Downes, CEJ; McClure, BJ; Bruning, JB; Page, E; Breen, J; Rehn, J; Yeung, DT; White, DL

White, DL (corresponding author), South Australian Hlth & Med Res Inst SAHMRI, Precis Med Theme, Canc Program, Adelaide, SA, Australia.; White, DL (corresponding author), Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia.; White, DL (corresponding author), Univ Adelaide, Fac Hlth & Med Sci, Adelaide, SA, Australia.; White, DL (corresponding author), Murdoch Childrens Res Inst, Australian Genom Hlth Alliance AGHA, Parkville, Vic, Australia.; White, DL (corresponding author), Australian & New Z

NPJ PRECISION ONCOLOGY, 2021; 5 (1):

Abstract

Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索